| scholarly article | Q13442814 |
| P50 | author | Walter C. Willett | Q1133904 |
| Graham Colditz | Q5592728 | ||
| A Heather Eliassen | Q58872929 | ||
| Bernard A. Rosner | Q76570651 | ||
| Susan E. Hankinson | Q76570836 | ||
| Sara Lindstroem | Q77022171 | ||
| Peter Kraft | Q77526208 | ||
| Rulla M Tamimi | Q88477882 | ||
| Xuehong Zhang | Q88882301 | ||
| Amit D Joshi | Q90228066 | ||
| Shelley S. Tworoger | Q46915135 | ||
| P2093 | author name string | Jing Qian | |
| Megan Rice | |||
| P2860 | cites work | Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women: a prospective cohort study | Q24810284 |
| The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation | Q28137833 | ||
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| Urinary melatonin and risk of ovarian cancer | Q28388517 | ||
| The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women | Q29396434 | ||
| Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
| Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. | Q30620197 | ||
| Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies | Q30657567 | ||
| Validation of Rosner-Colditz breast cancer incidence model using an independent data set, the California Teachers Study | Q30683824 | ||
| Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study | Q31161296 | ||
| Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention | Q32133889 | ||
| Converting relative risks to absolute risks: a graphical approach. | Q52530980 | ||
| Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort | Q57026268 | ||
| Projecting individualized probabilities of developing breast cancer for white females who are being examined annually | Q69396132 | ||
| Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. | Q40089754 | ||
| Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort | Q40314089 | ||
| The Nurses' Health Study | Q40382857 | ||
| Toward excellence in testosterone testing: a consensus statement | Q42868204 | ||
| Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women | Q44053417 | ||
| Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women | Q45188730 | ||
| Power and sample size estimation for the Wilcoxon rank sum test with application to comparisons of C statistics from alternative prediction models | Q45218406 | ||
| Breast cancer risk prediction with a log-incidence model: evaluation of accuracy | Q47610433 | ||
| Validation studies for models projecting the risk of invasive and total breast cancer incidence. | Q50651945 | ||
| Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. | Q50867313 | ||
| Genetics and breast cancer risk prediction--are we there yet? | Q51646417 | ||
| Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. | Q51933968 | ||
| Comparison of estrogen receptor results from pathology reports with results from central laboratory testing | Q33582502 | ||
| Performance of common genetic variants in breast-cancer risk models | Q34064069 | ||
| Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer | Q34225990 | ||
| Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information | Q34267477 | ||
| Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer | Q34736112 | ||
| Overview of the main outcomes in breast-cancer prevention trials | Q35057371 | ||
| Joint effects of colorectal cancer susceptibility loci, circulating 25-hydroxyvitamin D and risk of colorectal cancer | Q35132050 | ||
| Prospective approach to breast cancer risk prediction in African American women: the black women's health study model | Q35168773 | ||
| Nondense mammographic area and risk of breast cancer | Q35683591 | ||
| Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies | Q35852411 | ||
| Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
| The Nurses' Health Study: lifestyle and health among women | Q36111939 | ||
| The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
| SNPs and breast cancer risk prediction for African American and Hispanic women | Q36322904 | ||
| Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement | Q36393193 | ||
| Mammographic density, breast cancer risk and risk prediction | Q36465317 | ||
| Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests | Q36495833 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up | Q36638994 | ||
| A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. | Q36713568 | ||
| Challenges to the measurement of estradiol: an endocrine society position statement | Q36736507 | ||
| Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II | Q36903340 | ||
| Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer | Q36955125 | ||
| A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development | Q37082963 | ||
| An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population | Q37170192 | ||
| Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model | Q37172219 | ||
| Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status | Q37223335 | ||
| Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model | Q37246495 | ||
| Enhancement of mammographic density measures in breast cancer risk prediction | Q37377626 | ||
| Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study | Q37681743 | ||
| A review of body size and breast cancer risk in Hispanic and African American women | Q37877651 | ||
| Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women | Q38480036 | ||
| Breast cancer risk prediction: an update to the Rosner-Colditz breast cancer incidence model | Q38681543 | ||
| Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States | Q39734134 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e1002644 | |
| P577 | publication date | 2018-09-04 | |
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study | |
| P478 | volume | 15 |
| Q92199197 | A systematic review and quality assessment of individualised breast cancer risk prediction models |
| Q92102602 | Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool |
| Q89746441 | Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field |
| Q89947285 | Effect of Physical Training on the Levels of Sex Hormones and the Expression of Their Receptors in Rats With Induced Mammary Cancer in Secondary Prevention Model - Preliminary Study |
| Q64080586 | Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer |
| Q94571796 | Identification of a six-gene signature associated with tumor mutation burden for predicting prognosis in patients with invasive breast carcinoma |
| Q91272324 | Identification of high-risk patients for ADR induced by traditional Chinese medicine injection: a nested case-control study |
| Q64279327 | Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk |
| Q91587413 | MRPS30-DT Knockdown Inhibits Breast Cancer Progression by Targeting Jab1/Cops5 |
| Q60936241 | Overexpression of MUC1 predicts poor prognosis in patients with breast cancer |
| Q92675127 | Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer |
| Q92277944 | Predicting breast cancer risk using personal health data and machine learning models |
| Q90744442 | Risk Models for Breast Cancer and Their Validation |
| Q91975781 | Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis |
Search more.